Neko Health valuation, funding and investors
Neko Health works in preventive healthcare services, based in Stockholm, Sweden. Founded in 2018, it has about 751 employees.
- Last round
- Series C · $700M · Jul 2026
- Valuation at last round
- $7.00B
- Headcount
- 751 · growing
- Grade
- A
- Founded
- 2018
Neko Health valuation today
VCMC values Neko Health at $7.6B today, with a range of $6.1B to $10.8B and a grade of A. The valuation starts from its last funding round, a Series C round in Jul 2026.
Valuation by date (110 rows)
Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.
| Date | Valuation | Range | Predicted in 1 yr | Phase | Headcount | Trend | Grade | Winding-down probability |
|---|---|---|---|---|---|---|---|---|
| 1 Jan 2018 | $5.66M | $2.06M – $15.6M | $7.76M (+37%) | before first round | – | unknown | D | 0% |
| 1 Feb 2018 | $5.82M | $2.12M – $16.0M | $7.97M (+37%) | before first round | – | unknown | D | 0% |
| 1 Mar 2018 | $5.96M | $2.17M – $16.4M | $8.17M (+37%) | before first round | – | unknown | D | 0% |
| 1 Apr 2018 | $6.12M | $2.23M – $16.8M | $8.39M (+37%) | before first round | – | unknown | D | 0% |
| 1 May 2018 | $6.28M | $2.29M – $17.3M | $8.61M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jun 2018 | $6.45M | $2.35M – $17.7M | $8.85M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jul 2018 | $6.62M | $2.41M – $18.2M | $9.08M (+37%) | before first round | – | unknown | D | 0% |
| 1 Aug 2018 | $6.80M | $2.48M – $18.7M | $9.17M (+35%) | before first round | – | unknown | D | 0% |
| 1 Sep 2018 | $6.99M | $2.54M – $19.2M | $9.25M (+32%) | before first round | – | unknown | D | 0% |
| 1 Oct 2018 | $7.17M | $2.61M – $19.7M | $9.34M (+30%) | before first round | – | unknown | D | 0% |
| 1 Nov 2018 | $7.36M | $2.68M – $20.2M | $9.42M (+28%) | before first round | – | unknown | D | 0% |
| 1 Dec 2018 | $7.56M | $2.75M – $20.8M | $9.51M (+26%) | before first round | – | unknown | D | 0% |
| 1 Jan 2019 | $7.76M | $2.83M – $21.3M | $9.59M (+24%) | before first round | – | unknown | D | 0% |
| 1 Feb 2019 | $7.97M | $2.90M – $21.9M | $9.68M (+21%) | before first round | – | unknown | D | 0% |
| 1 Mar 2019 | $8.17M | $2.97M – $22.4M | $9.76M (+19%) | before first round | – | unknown | D | 0% |
| 1 Apr 2019 | $8.39M | $3.05M – $23.1M | $9.85M (+17%) | before first round | – | unknown | D | 0% |
| 1 May 2019 | $8.61M | $3.14M – $23.7M | $9.94M (+15%) | before first round | – | unknown | D | 0% |
| 1 Jun 2019 | $8.85M | $3.22M – $24.3M | $10.0M (+13%) | before first round | – | unknown | D | 0% |
| 1 Jul 2019 | $9.08M | $3.30M – $24.9M | $10.1M (+11%) | before first round | – | unknown | D | 0% |
| 1 Aug 2019 | $9.17M | $3.34M – $25.2M | $10.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 Sep 2019 | $9.25M | $3.37M – $25.4M | $10.3M (+11%) | before first round | – | unknown | D | 0% |
| 1 Oct 2019 | $9.34M | $3.40M – $25.6M | $10.4M (+11%) | before first round | – | unknown | D | 0% |
| 1 Nov 2019 | $9.42M | $3.43M – $25.9M | $10.5M (+11%) | before first round | – | unknown | D | 0% |
| 1 Dec 2019 | $9.51M | $3.46M – $26.1M | $10.6M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jan 2020 | $9.59M | $3.49M – $26.4M | $10.7M (+11%) | before first round | – | unknown | D | 0% |
| 1 Feb 2020 | $9.68M | $3.52M – $26.6M | $10.8M (+11%) | before first round | – | unknown | D | 0% |
| 1 Mar 2020 | $9.76M | $3.55M – $26.8M | $10.9M (+11%) | before first round | – | unknown | D | 0% |
| 1 Apr 2020 | $9.85M | $3.59M – $27.1M | $11.0M (+11%) | before first round | – | unknown | D | 0% |
| 1 May 2020 | $9.94M | $3.62M – $27.3M | $11.1M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jun 2020 | $10.0M | $3.65M – $27.6M | $11.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jul 2020 | $10.1M | $3.69M – $27.8M | $11.3M (+11%) | before first round | – | unknown | D | 0% |
| 1 Aug 2020 | $10.2M | $3.72M – $28.1M | $11.4M (+11%) | before first round | – | unknown | D | 0% |
| 1 Sep 2020 | $10.3M | $3.75M – $28.3M | $11.5M (+11%) | before first round | – | unknown | D | 0% |
| 1 Oct 2020 | $10.4M | $3.79M – $28.6M | $11.6M (+11%) | before first round | – | unknown | D | 0% |
| 1 Nov 2020 | $10.5M | $3.82M – $28.8M | $11.7M (+11%) | before first round | – | unknown | D | 0% |
| 1 Dec 2020 | $10.6M | $3.86M – $29.1M | $11.8M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jan 2021 | $10.7M | $3.89M – $29.3M | $11.9M (+11%) | before first round | – | unknown | D | 0% |
| 1 Feb 2021 | $10.8M | $3.93M – $29.6M | $12.0M (+11%) | before first round | – | unknown | D | 0% |
| 1 Mar 2021 | $10.9M | $3.96M – $29.9M | $12.1M (+11%) | before first round | – | unknown | D | 0% |
| 1 Apr 2021 | $11.0M | $3.99M – $30.1M | $12.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 May 2021 | $11.1M | $4.03M – $30.4M | $12.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jun 2021 | $11.2M | $4.07M – $30.7M | $12.3M (+10%) | before first round | – | unknown | D | 0% |
| 1 Jul 2021 | $11.3M | $4.10M – $31.0M | $12.4M (+10%) | before first round | – | unknown | D | 0% |
| 1 Aug 2021 | $11.4M | $4.14M – $31.2M | $12.5M (+10%) | before first round | – | unknown | D | 0% |
| 1 Sep 2021 | $11.5M | $4.18M – $31.5M | $12.6M (+10%) | before first round | – | unknown | D | 0% |
| 1 Oct 2021 | $11.6M | $4.22M – $31.8M | $12.7M (+10%) | before first round | – | unknown | D | 0% |
| 1 Nov 2021 | $11.7M | $4.25M – $32.1M | $12.8M (+10%) | before first round | – | unknown | D | 0% |
| 1 Dec 2021 | $11.8M | $4.29M – $32.4M | $12.9M (+9%) | before first round | – | unknown | D | 0% |
| 1 Jan 2022 | $11.9M | $4.33M – $32.7M | $13.0M (+9%) | before first round | – | unknown | D | 0% |
| 1 Feb 2022 | $12.0M | $4.36M – $32.9M | $13.1M (+9%) | before first round | – | unknown | D | 0% |
| 1 Mar 2022 | $12.1M | $4.39M – $33.2M | $13.2M (+9%) | before first round | – | unknown | D | 0% |
| 1 Apr 2022 | $12.2M | $4.43M – $33.4M | $13.3M (+9%) | before first round | – | unknown | D | 0% |
| 1 May 2022 | $12.2M | $4.46M – $33.6M | $13.4M (+9%) | before first round | – | unknown | D | 0% |
| 1 Jun 2022 | $12.3M | $4.49M – $33.9M | $13.5M (+9%) | before first round | – | unknown | D | 0% |
| 1 Jul 2022 | $12.4M | $4.53M – $34.1M | $13.6M (+9%) | before first round | – | unknown | D | 0% |
| 1 Aug 2022 | $12.5M | $4.56M – $34.4M | $13.7M (+9%) | before first round | – | unknown | D | 0% |
| 1 Sep 2022 | $12.6M | $4.59M – $34.7M | $13.8M (+9%) | before first round | – | unknown | D | 0% |
| 1 Oct 2022 | $12.7M | $4.63M – $34.9M | $13.9M (+9%) | before first round | – | unknown | D | 0% |
| 1 Nov 2022 | $12.8M | $4.66M – $35.2M | $14.0M (+9%) | before first round | – | unknown | D | 0% |
| 1 Dec 2022 | $12.9M | $4.70M – $35.4M | $14.1M (+9%) | before first round | – | unknown | D | 0% |
| 1 Jan 2023 | $13.0M | $4.73M – $35.7M | $14.2M (+9%) | before first round | – | unknown | D | 0% |
| 1 Feb 2023 | $13.1M | $4.77M – $36.0M | $14.3M (+9%) | before first round | – | unknown | D | 0% |
| 1 Mar 2023 | $13.2M | $4.80M – $36.2M | $14.4M (+9%) | before first round | – | unknown | D | 0% |
| 1 Apr 2023 | $15.3M | $5.56M – $41.9M | $16.7M (+9%) | before first round | 38 | unknown | D | 0% |
| 1 May 2023 | $15.4M | $5.60M – $42.2M | $16.8M (+9%) | before first round | 38 | unknown | D | 0% |
| 1 Jun 2023 | $15.5M | $5.64M – $42.6M | $16.9M (+9%) | before first round | 38 | unknown | D | 0% |
| 1 Jul 2023 | $15.6M | $5.68M – $42.9M | $17.0M (+9%) | before first round | 38 | unknown | D | 0% |
| 6 Jul 2023 | $333M | $219M – $912M | $599M (+80%) | after a round | 38 | unknown | C | 0% |
| 1 Aug 2023 | $348M | $219M – $912M | $599M (+72%) | after a round | 38 | unknown | C | 0% |
| 1 Sep 2023 | $365M | $219M – $912M | $599M (+64%) | after a round | 38 | unknown | C | 0% |
| 1 Oct 2023 | $384M | $219M – $912M | $599M (+56%) | after a round | 58 | growing | C | 0% |
| 1 Nov 2023 | $403M | $219M – $912M | $599M (+49%) | after a round | 58 | growing | C | 0% |
| 1 Dec 2023 | $423M | $219M – $912M | $599M (+42%) | after a round | 58 | growing | C | 0% |
| 1 Jan 2024 | $445M | $219M – $912M | $599M (+35%) | after a round | 58 | growing | C | 0% |
| 1 Feb 2024 | $476M | $226M – $941M | $619M (+30%) | after a round | 67 | growing | C | 0% |
| 1 Mar 2024 | $500M | $226M – $941M | $619M (+24%) | after a round | 67 | growing | C | 0% |
| 1 Apr 2024 | $527M | $226M – $941M | $619M (+17%) | after a round | 67 | growing | C | 0% |
| 1 May 2024 | $555M | $226M – $941M | $619M (+12%) | after a round | 67 | growing | C | 0% |
| 1 Jun 2024 | $585M | $226M – $941M | $619M (+6%) | after a round | 67 | growing | C | 0% |
| 1 Jul 2024 | $667M | $245M – $1.0B | $671M (+1%) | after a round | 97 | growing | C | 0% |
| 1 Aug 2024 | $671M | $248M – $1.0B | $671M (0%) | after a round | 97 | growing | C | 0% |
| 1 Sep 2024 | $671M | $252M – $1.0B | $671M (0%) | after a round | 97 | growing | C | 0% |
| 1 Oct 2024 | $671M | $255M – $1.0B | $671M (0%) | after a round | 97 | growing | C | 0% |
| 1 Nov 2024 | $716M | $276M – $1.1B | $716M (0%) | after a round | 130 | growing | C | 0% |
| 1 Dec 2024 | $716M | $280M – $1.1B | $716M (0%) | after a round | 130 | growing | C | 0% |
| 1 Jan 2025 | $716M | $284M – $1.1B | $716M (0%) | after a round | 130 | growing | C | 0% |
| 24 Jan 2025 | $1.8B | $1.6B – $3.1B | $2.7B (+50%) | after a round | 130 | growing | B | 0% |
| 1 Feb 2025 | $1.8B | $1.6B – $3.1B | $2.7B (+49%) | after a round | 130 | growing | B | 0% |
| 1 Mar 2025 | $1.9B | $1.6B – $3.1B | $2.7B (+44%) | after a round | 130 | growing | B | 0% |
| 1 Apr 2025 | $1.9B | $1.6B – $3.1B | $2.7B (+39%) | after a round | 130 | growing | B | 0% |
| 1 May 2025 | $2.0B | $1.6B – $3.1B | $2.7B (+35%) | after a round | 130 | growing | B | 0% |
| 1 Jun 2025 | $2.1B | $1.6B – $3.1B | $2.7B (+30%) | after a round | 130 | growing | B | 0% |
| 1 Jul 2025 | $2.1B | $1.6B – $3.1B | $2.7B (+26%) | after a round | 130 | growing | B | 0% |
| 1 Aug 2025 | $2.4B | $1.6B – $3.6B | $3.1B (+30%) | after a round | 247 | growing | B | 0% |
| 1 Sep 2025 | $2.5B | $1.6B – $3.6B | $3.1B (+24%) | after a round | 247 | growing | B | 0% |
| 1 Oct 2025 | $2.6B | $1.6B – $3.6B | $3.1B (+19%) | after a round | 247 | growing | B | 0% |
| 1 Nov 2025 | $2.9B | $1.6B – $3.8B | $3.3B (+15%) | after a round | 312 | growing | B | 0% |
| 1 Dec 2025 | $3.0B | $1.6B – $3.8B | $3.3B (+9%) | after a round | 312 | growing | B | 0% |
| 1 Jan 2026 | $3.2B | $1.6B – $3.8B | $3.3B (+4%) | after a round | 312 | growing | B | 0% |
| 1 Feb 2026 | $3.3B | $1.6B – $3.8B | $3.3B (0%) | after a round | 312 | growing | B | 0% |
| 1 Mar 2026 | $3.3B | $1.6B – $3.8B | $3.3B (0%) | after a round | 312 | growing | B | 0% |
| 1 Apr 2026 | $3.3B | $1.7B – $3.8B | $3.3B (0%) | after a round | 312 | growing | B | 0% |
| 1 May 2026 | $3.8B | $1.8B – $4.3B | $3.8B (0%) | after a round | 588 | growing | B | 0% |
| 1 Jun 2026 | $3.8B | $1.8B – $4.3B | $3.8B (0%) | after a round | 588 | growing | B | 0% |
| 1 Jul 2026 | $3.8B | $1.9B – $4.3B | $3.8B (0%) | after a round | 588 | growing | B | 0% |
| 16 Jul 2026 | $7.0B | $6.1B – $10.5B | $9.1B (+30%) | after a round | 648 | growing | A | 0% |
| 1 Aug 2026 | $7.1B | $6.1B – $10.5B | $9.1B (+28%) | after a round | 648 | growing | A | 0% |
| 1 Sep 2026 | $7.2B | $6.1B – $10.5B | $9.1B (+26%) | after a round | 648 | growing | A | 0% |
| 1 Oct 2026 | $7.5B | $6.1B – $10.8B | $9.4B (+26%) | after a round | 751 | growing | A | 0% |
| 24 Oct 2026 | $7.6B | $6.1B – $10.8B | $9.4B (+24%) | after a round | 751 | growing | A | 0% |
Key facts about Neko Health
- Founded
- 2018
- Headquarters
- Stockholm, Sweden
- Employees
- about 751 +141% in a year
- Total raised
- $1.03B
- Funding rounds
- 3
- Last round
- Series C Jul 2026
Neko Health was founded in 2018 by Daniel Ek and Hjalmar Nilsonne.
Neko Health funding history
Neko Health has 3 funding rounds on record, from Jul 2023 to Jul 2026, $1.03B in total. The latest disclosed valuation is $7.00B post-money (Series C, Jul 2026).
Series C 15 Jul 2026
Led by Lightspeed Venture Partners, O.G. Venture Partners; with Atomico, General Catalyst, Lakestar, Liberty City Ventures, Positive Sum, BDT & MSD Partners. Individuals: Mark Zuckerberg, Priscilla Chan, Jimmy Iovine, Maria Sharapova, Thierry Henry, Tim Ferriss, will.i.am, Alexis Ohanian, Zoë Saldaña, Ari Emanuel, Matthew Vaughn, Danny Meyer, Gary Vaynerchuk, Steven Bartlett, Jessie Inchauspé.
Sources: nekohealth.com, techcrunch.com, med-tech.world and 1 more
$700M
$7.00B post-money
Series B 23 Jan 2025
Led by Lightspeed Venture Partners; with General Catalyst, O.G. Venture Partners, Rosello, Lakestar, Atomico.
Sources: nekohealth.com, htn.co.uk, medtechdive.com and 5 more
$260M
$1.80B post-money
Series A 5 Jul 2023
Led by Lakestar; with Atomico, General Catalyst.
Sources: nekohealth.com, mobihealthnews.com
$65M
Neko Health investors
9 investors have backed Neko Health; Lakestar, Lightspeed Venture Partners and O.G. Venture Partners led at least one round.
- Lakestar lead, 3 rounds
- Lightspeed Venture Partners lead, 2 rounds
- Atomico 3 rounds
- General Catalyst 3 rounds
- BDT & MSD Partners
- Liberty City Ventures
- Positive Sum
- Rosello
What Neko Health does
Neko Health works in health care services, with 12 recorded offerings and customers in healthcare.
Neko Health AB is a Swedish company that operates as a healthcare provider and health-tech firm. The company delivers preventive healthcare services, including health assessments and medical scanning technology, and manages health centers in Sweden and the UK. Neko Health also conducts clinical studies to support diagnostic capabilities and patient safety, and is involved in the development of medical scanning technology and artificial intelligence applications for health monitoring.
Description from Veridion's company data.
Products and services
- Preventive Healthcare Services
- Body Scan Health Assessment Services
- Personalized Health Tracking Services
- Doctor-Led Health Examination Services
- Non-Invasive Health Data Collection
- AI-Driven Health Data Analysis
- Clinical Study Participation Services
- Advanced Medical Sensor Development
- Preventive Healthcare Technology Research
- Health Data Analytics Services
- Early Disease Detection Solutions
- Strategic Healthcare Partnership Development
Markets
- Healthcare
Technology
- Advanced Sensors for Non-Invasive Health Data Collection
- Artificial Intelligence for Disease Detection
- High-Quality Imaging for Comprehensive Health Data Capture
Business model
- Business-to-Consumer
- Service Provider
- Healthcare
Industry codes (NAICS)
- 621498 All Other Outpatient Care Centers 75% match
- 541512 Computer Systems Design Services 25% match
Questions about Neko Health
What is Neko Health worth?
Valuation $7.6B (range $6.1B to $10.8B), as of 24 Oct 2026. The last disclosed valuation was $7.00B (Series C, Jul 2026).
Has Neko Health raised money?
Neko Health has 3 funding rounds on record, from Jul 2023 to Jul 2026, $1.03B in total. The latest disclosed valuation is $7.00B post-money (Series C, Jul 2026).
Who has invested in Neko Health?
Lakestar, Lightspeed Venture Partners, O.G. Venture Partners, Atomico, General Catalyst and BDT & MSD Partners, and 3 more. Lead investors include Lakestar, Lightspeed Venture Partners and O.G. Venture Partners.
How many people work at Neko Health?
About 751, up 141% over the last year. Headcount grew from 38 in Apr 2023 to 751 in Sep 2026.
What does Neko Health do?
Neko Health works in health care services, with 12 recorded offerings and customers in healthcare. Its main offerings are preventive healthcare services, body scan health assessment services and personalized health tracking services.
When was Neko Health founded, and where is it based?
Neko Health was founded in 2018 and is based in Stockholm, Sweden. It has about 751 employees, up 141% over the last year.